Shares of GlaxoSmithKline plc (NYSE:GSK) have been given an average recommendation of “Hold” by the twenty-one brokerages that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $37.71.
A number of equities analysts recently weighed in on GSK shares. BidaskClub upgraded shares of GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Argus reiterated a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline in a report on Thursday, August 31st. Morgan Stanley lowered shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 14th. Finally, Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Wednesday, October 18th.
GlaxoSmithKline (NYSE:GSK) traded down $0.34 on Monday, reaching $35.24. 7,245,928 shares of the company were exchanged, compared to its average volume of 3,560,087. The firm has a market capitalization of $87,356.00, a price-to-earnings ratio of 12.60, a PEG ratio of 1.97 and a beta of 0.98. GlaxoSmithKline has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.
In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.
Several large investors have recently made changes to their positions in the business. Proficio Capital Partners LLC boosted its holdings in shares of GlaxoSmithKline by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after buying an additional 457 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in shares of GlaxoSmithKline by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 64 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its holdings in shares of GlaxoSmithKline by 1,982.8% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after buying an additional 3,351 shares in the last quarter. FTB Advisors Inc. boosted its holdings in shares of GlaxoSmithKline by 16.9% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after buying an additional 539 shares in the last quarter. Finally, Advisory Services Network LLC boosted its holdings in shares of GlaxoSmithKline by 24.2% in the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after buying an additional 788 shares in the last quarter. 9.83% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Receives $37.71 Average Target Price from Brokerages” was first reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://weekherald.com/2017/12/14/glaxosmithkline-plc-gsk-receives-37-71-average-target-price-from-brokerages.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.